Cargando…

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis

OBJECTIVES: We hypothesise that patients have a positive sentiment regarding biological/targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) and a negative sentiment towards conventional synthetic agents (csDMARDs). We analysed discussions on social media platforms regarding DMARDs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Chanakya, Whittle, Samuel, Haghighi, Pari Delir, Burstein, Frada, Sa'adon, Roee, Keen, Helen Isobel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569383/ https://www.ncbi.nlm.nih.gov/pubmed/32883653 http://dx.doi.org/10.1136/annrheumdis-2020-217333

Ejemplares similares

Sentiment analysis of social media posts on pharmacotherapy: A scoping review
por: Sharma, Chanakya, et al.
Publicado: (2020)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
por: Novella -Navarro, Marta, et al.
Publicado: (2023)

Qualitative Study of Treatment Preferences for Rheumatoid Arthritis and Pharmacotherapy Acceptance: Indigenous Patient Perspectives
por: Loyola‐Sanchez, Adalberto, et al.
Publicado: (2020)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
por: Redeker, Imke, et al.
Publicado: (2022)

Mining the pathogenesis of rheumatoid arthritis, the leading role of the environment
por: Adami, Giovanni
Publicado: (2022)

Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study
por: Norvang, Vibeke, et al.
Publicado: (2018)

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis
por: Baradat, Claire, et al.
Publicado: (2017)

Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)
por: Fleischmann, Roy M, et al.
Publicado: (2023)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial
por: Hebing, Renske CF, et al.
Publicado: (2022)

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries
por: Delcoigne, Benedicte, et al.
Publicado: (2022)

Vaccine Adverse Event Mining of Twitter Conversations: 2-Phase Classification Study
por: Khademi Habibabadi, Sedigheh, et al.
Publicado: (2022)

Advances in E-Health and Mobile Health Monitoring
por: Delir Haghighi, Pari, et al.
Publicado: (2022)

Investigating Individuals’ Perceptions Regarding the Context Around the Low Back Pain Experience: Topic Modeling Analysis of Twitter Data
por: Delir Haghighi, Pari, et al.
Publicado: (2021)

Trajectories of self-reported pain-related health outcomes and longitudinal effects on medication use in rheumatoid arthritis: a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
por: Pisaniello, Huai Leng, et al.
Publicado: (2023)

Glucocorticoids and chronotherapy in rheumatoid arthritis
por: Cutolo, Maurizio
Publicado: (2016)

Management of Fatigue in Rheumatoid Arthritis
por: Pope, Janet E
Publicado: (2020)

Features of the Synovium of Individuals at Risk of Developing Rheumatoid Arthritis: Implications for Understanding Preclinical Rheumatoid Arthritis
por: de Hair, MJH, et al.
Publicado: (2014)

Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis
por: Motta, Francesca, et al.
Publicado: (2023)

Interplay between obesity and smoking with regard to RA risk
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Biologicals in rheumatoid arthritis: current and future
por: Avci, Ali Berkant, et al.
Publicado: (2015)

Don’t neglect nutrition in rheumatoid arthritis!
por: Cutolo, Maurizio, et al.
Publicado: (2018)

Rheumatoid arthritis prevention: any takers?
por: Falahee, Marie, et al.
Publicado: (2021)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
por: Ferreira, Ricardo J O, et al.
Publicado: (2022)

Intermetatarsal bursitis is frequent in patients with established rheumatoid arthritis and is associated with anti-cyclic citrullinated peptide and rheumatoid factor
por: Hammer, Hilde Berner, et al.
Publicado: (2019)

Differences in the Oral Microbiome in Patients With Early Rheumatoid Arthritis and Individuals at Risk of Rheumatoid Arthritis Compared to Healthy Individuals
por: Kroese, Johanna M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7il2na7p4c1aq02e3cjtkc2okf